These in vitro data suggested that crosslinking through tumor target binding was required for FcγR-mediated effector cell activation and is analogous to the ability of crosslinking through FcγR engagement to promote signaling through TweakR as discussed above. This evidence concerns the gene TNFRSF12A and neoplasm.